摘要
胰腺导管腺癌(PDA)仍然是全球范围内一个毁灭性的疾病。虽然其病理生理学研究方面已取得显著进展,但PDA患者仅少数蛋白可能从治疗性手术和当前化疗中受益。因此,目前迫切需要开发新的有效治疗方法用于PDA的治疗。目前,大蒜产品已作为治疗癌症的一个有效的重要药物来源。最近,我们鉴定了大蒜新的活性成分,S-炔丙基-L-半胱氨酸(SPRC)、S-烯丙基半胱氨酸(SAC)的类似物。虽然已经显示出对几种癌症的抗癌活性,但其作用机制尚不完全清楚。本研究旨在首次确定PDA中SPRC的抗癌活性及其体外和体内的潜在作用机制。我们的研究结果表明,SPRC降低细胞活力和集落形成,抑制细胞增殖,诱导G2/M期具有不同p53状态的PDA细胞周期阻滞和凋亡。此外,SPRC在Panc-1异种移植模型中抑制肿瘤生长。我们还表明,SPRC通过增加其磷酸化,并降低其泛素化介导的降解JNK蛋白水平的调控作用实现其抗癌作用。总之,SPRC具有显著的抗PDA活性和效果且不依赖于p53,可能是通过激活JNK信号传导通路起作用,作为一种新的PDA靶向抗癌治疗剂,为开发该化合物提供基础。
关键词: 凋亡,化疗,大蒜衍生物,JNK,胰腺癌,S-炔丙基-L-半胱氨酸
Current Cancer Drug Targets
Title:The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo
Volume: 15 Issue: 7
Author(s): Wei Wang, Jianwen Cheng and Yizhun Zhu
Affiliation:
关键词: 凋亡,化疗,大蒜衍生物,JNK,胰腺癌,S-炔丙基-L-半胱氨酸
摘要: Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease worldwide. Although significant improvement has been made in understanding its pathophysiology, only small portion of patients with PDA are likely to benefit from curative surgery and current chemotherapy. Thus, there is an urgent need for developing novel effective therapeutic approaches to the treatment of PDA. Today, garlic products have become an important source of effective compounds for the treatment of cancer. We have recently identified a novel garlic active component, S-propargyl-L-cysteine (SPRC), an analogue of S-Allyl Cysteine (SAC). Although its anticancer activity has been shown against several cancers, the mechanism of action is not fully understood. The present study was first designed to determine the anticancer activity of SPRC in PDA and the underlying mechanisms of action in vitro and in vivo. Our results demonstrated that SPRC reduced cell viability and colony formation, inhibited cell proliferation, induced G2/M phase cell cycle arrest and apoptosis in human PDA cells with various p53 statuses (HPAC, p53 wt; Panc-1, p53 mt). Furthermore, SPRC inhibited tumor growth in Panc-1 xenograft models. We also demonstrated that SPRC achieved its anticancer effects by regulation of the JNK protein levels through increasing its phosphorylation and decreasing its polyubiquitination-mediated degradation. In conclusion, SPRC has significant anti-PDA activity and the effects do not depend on p53 status, presumably through activating the JNK signaling pathway, providing a basis for the development of this compound as a novel target anticancer therapeutic agent for PDA.
Export Options
About this article
Cite this article as:
Wei Wang, Jianwen Cheng and Yizhun Zhu , The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150602143943
DOI https://dx.doi.org/10.2174/1568009615666150602143943 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters 18F-Containing Positron Emission Tomography Probe Conjugation Methodology for Biologics as Specific Binders for Tumors
Current Topics in Medicinal Chemistry Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Letters in Drug Design & Discovery Principles of Minimally Invasive Parathyroidectomy
Current Medical Imaging Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole
Letters in Drug Design & Discovery Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Tankyrase Inhibitors as Therapeutic Targets for Cancer
Current Topics in Medicinal Chemistry Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy